about
The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populationsIdentification, cloning, expression, and biochemical characterization of the testis-specific RNA polymerase II elongation factor ELL3Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis.A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathwayThe human interferon-inducible protein, IFI 16, is a repressor of transcriptionRole of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescenceCloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanomaA novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1Isotypic variants of the interferon-inducible transcriptional repressor IFI 16 arise through differential mRNA splicingNovel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motifNew and emerging HDAC inhibitors for cancer treatmentStructures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 ReceptorConstitutive type I interferon modulates homeostatic balance through tonic signalingUV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell CarcinomasThe histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen speciesInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyInhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Anticancer activities of histone deacetylase inhibitorsGranzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.Cloning and characterisation of Ifi206: a new murine HIN-200 family member.Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitorsFunctional crosstalk between type I and II interferon through the regulated expression of STAT1.Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationIdentification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2.Mapping of the human PAWR (par-4) gene to chromosome 12q21.Apoptosis: a link between cancer genetics and chemotherapy.The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyEradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsHistone-deacetylase inhibitors: novel drugs for the treatment of cancer.
P50
Q22003925-D9198AF6-7402-4A2A-9FF4-30CAC6D04ECBQ22254564-B5732FBC-CE4A-4B88-BAF1-EB97C337B846Q24292352-9DBB4E05-7543-4914-BBEC-4B31A96AE256Q24301011-F2E6223A-F1C6-48BF-A082-16ABCD7FD069Q24310302-03EE0D05-C112-4C52-9F51-30234F3C9C56Q24313236-194A5F4F-1C2C-4C77-8D27-E17D61896BCAQ24320063-A2D6626F-6F11-4A51-BBCA-71D7097CDA25Q24324095-32F8C690-0FEF-4C29-9F40-B43F829DB341Q24336830-1BBD7344-7016-43B8-AF35-2F6C0EAA7185Q24532235-C13CCC6E-171E-45F9-A7F4-51D35DEB4352Q24682801-14E6F004-2F99-4133-B4B4-61F9860B4EE1Q27022413-C0DF332F-B4FB-4C83-B870-C1C718093B9BQ27678368-9DBAB875-EFD5-49CF-A379-8954B7E181EFQ28260631-320389CA-783A-4DAA-A406-16B122518427Q28270523-D51E49C4-B2E2-4078-8932-89CA231520C3Q28349324-B078D242-4CCA-4C15-AE7A-2ECF471E24FAQ28468631-FBFBD7F1-DD5F-4585-A8C4-F06BD69FE87EQ28544949-9128FDE4-726B-4706-8951-A64D3A8C039FQ28589774-BD485654-FD42-41D2-B4A0-7334849EF5A9Q29616624-CDE76DE4-7A3B-4010-AACC-ED6457581D8EQ30523061-15E4AAC9-8C3E-40FF-B0D0-79BBDF21EF6EQ30832305-DB3A266C-86FA-47A6-A8ED-161137DE2566Q33297045-C29675FB-187B-43C6-8377-5498FCCE05B1Q33393976-4B6D31B4-F29F-429D-929A-863B9FDD2BECQ33397154-771736AC-DABE-4C78-8E62-6A43F781393AQ33409828-5D83615A-5ACF-4CFB-B292-76127F496A4EQ33570493-01099986-2A7B-4B6D-B188-BC417BBDD251Q33731216-D1D7AA33-FF08-44B5-99A0-E1934B888373Q33926864-73A2B005-6D4E-4AD2-BA7E-EB6F935D6D16Q33946905-8053CAAD-7DBF-43EE-895D-EF9326E60A2DQ34048020-28216898-EFDA-40CF-B696-7ED910F0E058Q34263870-46373981-64F5-4C49-864F-632891E1FE08Q34374036-247BFA46-B8A2-408E-9AB9-022732752F6BQ34477431-E5C9938C-1930-4A7A-9828-92DDB79F988AQ34520432-DBFF030C-1C7F-438B-A2B6-3803536B91F9Q34527239-33D1D117-BBF9-4E1C-8857-508B2C2014C7Q34550649-5715A86F-19CA-4F3D-8736-89307C928905Q34652570-4EBB61F9-1F89-4D99-A9DE-D48AE89CFD00Q34658892-CA741296-566C-4C79-802C-A0FC1A334AD4Q34743301-E5C08480-DEDD-41E1-9914-FA75A8657CBD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ricky W Johnstone
@ast
Ricky W Johnstone
@en
Ricky W Johnstone
@es
Ricky W Johnstone
@nl
Ricky W Johnstone
@sl
type
label
Ricky W Johnstone
@ast
Ricky W Johnstone
@en
Ricky W Johnstone
@es
Ricky W Johnstone
@nl
Ricky W Johnstone
@sl
altLabel
RW Johnstone
@en
Ricky W Johnstone
@en
prefLabel
Ricky W Johnstone
@ast
Ricky W Johnstone
@en
Ricky W Johnstone
@es
Ricky W Johnstone
@nl
Ricky W Johnstone
@sl
P1053
H-3748-2014
P106
P21
P31
P3829
P496
0000-0001-7053-9237
P569
2000-01-01T00:00:00Z